Repatha (Evolocumab) Food & Supplement Interactions: What to Know Before You Inject

How Evolocumab Works (and Why Food Interactions Are Rare)

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein the liver secretes to tag LDL receptors for degradation. By blocking PCSK9, evolocumab keeps more LDL receptors active on the hepatocyte surface, pulling LDL-C out of the bloodstream at a faster rate.

Why the Mechanism Matters for Interactions

Most oral cholesterol drugs, statins included, travel through the gut, enter the portal circulation, and get metabolized by CYP450 enzymes in the liver. Grapefruit juice, for instance, inhibits intestinal CYP3A4 and can raise atorvastatin exposure by up to 2.5-fold [1]. Evolocumab bypasses this pathway entirely. It is injected subcutaneously, absorbed through the lymphatic system, and eventually broken down by the same proteolytic processes that clear all endogenous immunoglobulins [2].

What the FDA Label Says

The Repatha prescribing information contains no food interaction warnings and no supplement contraindications [2]. This is consistent across all PCSK9 inhibitors approved to date. The absence of CYP450 involvement means the usual suspects (grapefruit, St. John's wort, charcoal) do not alter evolocumab pharmacokinetics.

Clinical Nuance

"No direct food-drug interaction" does not mean diet and supplements are irrelevant. Several over-the-counter products affect the same lipid pathways evolocumab targets, and combining them without clinical oversight can confuse lab interpretation or introduce additive risks. The sections below cover each one.

Red Yeast Rice: A Hidden Statin in Supplement Form

Red yeast rice (RYR) contains monacolin K, which is chemically identical to lovastatin. The FDA has warned since 1998 that RYR products containing therapeutic levels of monacolin K are unapproved drugs [3]. Concentrations vary wildly across brands, ranging from <0.1 mg to over 10 mg per capsule in independent assays [4].

Why It Matters on Evolocumab

Most patients prescribed evolocumab are already on maximally tolerated statin therapy. The FOURIER trial enrolled patients on at least atorvastatin 20 mg or equivalent, and 69.3% were on high-intensity statins [5]. Adding RYR introduces an uncontrolled, variable-dose statin on top of this regimen.

The Risk

The primary concern is additive myopathy risk. A 2017 European Atherosclerosis Society consensus panel noted that patients who self-prescribe RYR alongside prescription statins face unpredictable dose stacking and should be screened at every visit [6]. If your provider has titrated your statin to balance efficacy and side effects, RYR can silently shift that balance.

The clinical recommendation is straightforward: disclose all RYR use to your prescriber, and do not substitute RYR for a prescribed statin without medical supervision.

Fish Oil (Omega-3 Fatty Acids)

Prescription omega-3 formulations (icosapent ethyl, omega-3 carboxylic acids) and over-the-counter fish oil capsules are among the most commonly co-administered supplements in patients with dyslipidemia.

What the Evidence Shows

The REDUCE-IT trial (N=8,179) demonstrated that icosapent ethyl 4 g/day reduced major cardiovascular events by 25% in statin-treated patients with elevated triglycerides [7]. Fish oil primarily lowers triglycerides, not LDL-C. Evolocumab primarily lowers LDL-C, not triglycerides. The two agents target complementary lipid fractions, and no pharmacokinetic interaction exists between them.

Practical Considerations

High-dose fish oil (above 3 g/day of combined EPA+DHA) can prolong bleeding time by inhibiting platelet aggregation [8]. Patients on concurrent anticoagulation or antiplatelet therapy should coordinate dosing with their care team. Standard doses of 1-2 g/day are generally well-tolerated alongside evolocumab.

One lab interpretation note: fish oil can raise LDL-C by 5-10% in some patients with hypertriglyceridemia, a phenomenon well-documented with DHA-containing formulations [8]. If your LDL-C rises unexpectedly after starting fish oil while on evolocumab, this is the likely explanation, not treatment failure.

Coenzyme Q10 (CoQ10)

CoQ10 supplementation is popular among statin users because statins inhibit HMG-CoA reductase, the same mevalonate pathway that produces endogenous CoQ10. Serum CoQ10 levels drop by approximately 40% on high-intensity statin therapy [9].

Interaction with Evolocumab

Evolocumab does not inhibit the mevalonate pathway and does not reduce CoQ10 synthesis. There is no pharmacological rationale for CoQ10 supplementation specifically because of PCSK9 inhibitor use. A patient on evolocumab alone (without a statin) would not experience statin-related CoQ10 depletion.

When CoQ10 Still Makes Sense

Since most evolocumab patients are also on a statin, CoQ10 supplementation may be reasonable for that statin component. A 2018 Cochrane review found limited evidence that CoQ10 reduces statin-associated muscle symptoms, though some patients report subjective benefit [10]. CoQ10 does not interfere with evolocumab's mechanism or its LDL-lowering efficacy.

Doses typically studied range from 100-300 mg daily. No dose adjustment of evolocumab is needed.

Niacin (Vitamin B3)

Niacin at pharmacological doses (1,000-2,000 mg/day) lowers LDL-C by 15-18% and raises HDL-C by 15-35%. It was once a mainstay of lipid therapy. Two large trials changed that trajectory.

The AIM-HIGH and HPS2-THRIVE Story

AIM-HIGH (N=3,414) found no incremental cardiovascular benefit from adding extended-release niacin to simvastatin therapy [11]. HPS2-THRIVE (N=25,673) confirmed the lack of benefit and documented increased risks of myopathy, gastrointestinal events, infections, and bleeding [12]. The 2018 ACC/AHA cholesterol guidelines now position niacin as a secondary option only when statins, ezetimibe, and PCSK9 inhibitors are insufficient or not tolerated [13].

Combining Niacin with Evolocumab

No pharmacokinetic interaction exists. The concern is clinical redundancy and additive side-effect burden. A patient on maximally tolerated statin plus evolocumab already has two powerful LDL-lowering agents working through distinct mechanisms. Adding niacin for marginal additional LDL reduction introduces flushing, hepatotoxicity risk, and glucose elevation without proven cardiovascular benefit in the modern treatment era.

If a patient is considering niacin, the prescriber should reassess whether ezetimibe (which has proven MACE reduction data from IMPROVE-IT) has been tried first [14].

Vitamin D

Vitamin D deficiency is common in cardiovascular patients. A 2019 meta-analysis of 83 observational studies found that low 25(OH)D levels correlate with increased cardiovascular events, though the VITAL trial (N=25,871) showed that vitamin D3 supplementation at 2,000 IU/day did not reduce major cardiovascular events in an unselected population [15].

Interaction Profile

Vitamin D does not interact with evolocumab pharmacokinetically or pharmacodynamically. Standard supplementation doses of 1,000-4,000 IU daily are safe to take concurrently. Some emerging research suggests vitamin D may modulate PCSK9 expression, with a small 2020 trial (N=82) showing that correcting vitamin D deficiency reduced circulating PCSK9 levels by 15% [16]. This is a hypothesis-generating finding, not a clinical recommendation. Do not adjust evolocumab dosing based on vitamin D status.

Berberine

Berberine, a plant alkaloid found in goldenseal and barberry, has gained popularity as a "natural statin." A 2020 meta-analysis of 27 RCTs (N=2,569) found that berberine reduces LDL-C by approximately 20-25 mg/dL and triglycerides by 25-35 mg/dL [17].

Mechanism Overlap

Berberine upregulates hepatic LDL receptor expression through a post-transcriptional mechanism distinct from both statins and PCSK9 inhibitors [17]. In theory, berberine and evolocumab could be complementary: evolocumab prevents PCSK9-mediated receptor degradation, while berberine increases receptor mRNA stability. No clinical trial has tested this combination.

Safety Concerns

Berberine inhibits CYP3A4 and CYP2D6, which does not affect evolocumab itself but could interact with co-prescribed statins metabolized by these enzymes (atorvastatin, lovastatin, simvastatin) [18]. A patient on atorvastatin plus evolocumab who adds berberine could see elevated statin blood levels, increasing myopathy risk. Disclose berberine use to your prescriber before starting or adjusting doses.

Berberine also lowers blood glucose and can cause gastrointestinal distress at doses above 1,000 mg/day.

Grapefruit and Grapefruit Juice

Grapefruit inhibits intestinal CYP3A4, a major concern for statins like atorvastatin, lovastatin, and simvastatin. Evolocumab is not metabolized by CYP3A4, so grapefruit has no direct effect on its levels or efficacy [2].

The Indirect Issue

If you take a CYP3A4-metabolized statin alongside evolocumab, grapefruit can still raise your statin exposure. This is a statin-grapefruit interaction, not an evolocumab-grapefruit interaction. Patients on rosuvastatin or pravastatin (which are not CYP3A4 substrates) can consume grapefruit without this concern.

St. John's Wort

St. John's wort is a potent CYP3A4 and P-glycoprotein inducer. It does not affect evolocumab directly. It can reduce the efficacy of co-prescribed medications that rely on CYP3A4, including certain statins and anticoagulants [19].

Clinical Guidance

If you take evolocumab as part of a multi-drug cardiovascular regimen, St. John's wort can undermine other components of that regimen without touching evolocumab itself. The interaction is indirect but clinically significant. Patients should inform their prescriber about St. John's wort use, especially if they are on warfarin, atorvastatin, or calcium channel blockers concurrently.

Plant Sterols and Stanols

Plant sterol-fortified foods and supplements (typically 2 g/day) reduce LDL-C by 6-15% by competing with cholesterol for intestinal absorption [20]. They work through a different mechanism than evolocumab and are safe to combine. The European Atherosclerosis Society consensus panel supports their use as an adjunct in patients not reaching LDL-C targets [6].

No dose adjustment of evolocumab is necessary. Plant sterols may provide a modest additive LDL-C reduction on top of statin plus evolocumab therapy.

Dietary Patterns and Evolocumab Efficacy

High-Fat Meals

Because evolocumab is injected, not swallowed, meal composition does not affect its absorption. There is no need to time injections around meals, and no food restriction applies on injection days.

Very Low-Carb and Ketogenic Diets

Ketogenic diets raise LDL-C in a subset of individuals, sometimes dramatically (the "lean mass hyper-responder" phenotype). A 2023 case series documented LDL-C increases of 100-200% in lean individuals adopting ketogenic diets [21]. If you are on evolocumab and switch to a ketogenic diet, monitor lipids at 4-6 weeks to catch any paradoxical LDL rise early.

Alcohol

Moderate alcohol consumption does not interact with evolocumab. Heavy alcohol use damages the liver and raises triglycerides, which can complicate the overall lipid management picture. This is a general cardiovascular risk concern, not an evolocumab-specific interaction.

Summary Table: Supplement Interactions at a Glance

| Supplement | Direct PK Interaction with Evolocumab | Indirect Clinical Concern | Action | |---|---|---|---| | Red yeast rice | None | Hidden statin dose stacking | Disclose to prescriber; avoid self-dosing | | Fish oil (omega-3) | None | May raise LDL-C (DHA); bleeding at high doses | Safe at standard doses; monitor lipids | | CoQ10 | None | None specific to evolocumab | Safe; relevant to statin co-therapy | | Niacin | None | Clinical redundancy; side-effect burden | Use only if statin + ezetimibe + PCSK9i insufficient | | Vitamin D | None | None | Safe at standard doses | | Berberine | None | CYP3A4 inhibition affects co-prescribed statins | Disclose to prescriber | | Grapefruit | None | CYP3A4 inhibition affects co-prescribed statins | No evolocumab concern; statin-dependent | | St. John's wort | None | CYP3A4 induction reduces statin/anticoagulant efficacy | Avoid or disclose | | Plant sterols | None | None | Safe; additive LDL-C lowering |

When to Call Your Prescriber

Contact your care team if you experience unexplained muscle pain or weakness after adding any supplement (especially RYR or berberine), if your LDL-C rises unexpectedly between visits, if you start or stop any supplement that affects liver enzymes (berberine, St. John's wort, high-dose niacin), or if you develop injection-site reactions that change in character after a dietary shift. Bring a complete supplement list to every lipid management appointment. Evolocumab itself carries a clean interaction profile, but the regimen around it often does not.